Skip to main content
Clinical Trials/EUCTR2020-001783-28-HU
EUCTR2020-001783-28-HU
Active, not recruiting
Phase 1

REDUCING ABSENCE FROM WORK OF HEALTHCARE WORKERS DUE TO COVID-19 INFECTION BY BCG (BACILLUS CALMETTE-GUÉRIN) VACCINATION - BACH (BCG Against COVID-19 in Hunga

ational Korányi Institute of Pulmonology0 sites1,000 target enrollmentApril 29, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
ational Korányi Institute of Pulmonology
Enrollment
1000
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 29, 2020
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
ational Korányi Institute of Pulmonology

Eligibility Criteria

Inclusion Criteria

  • In order to be eligible to participate in this study, a subject must meet the following criteria:
  • Adult (\>18 years)
  • Healthcare worker with direct contact with COVID\-19 positive patients
  • Written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 950
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 50

Exclusion Criteria

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • Fever (\>37,5 ºC) within the past 24 hours
  • Suspicion of current active viral or bacterial infection
  • Expected vaccination during the study period, independently of the type of vaccination.
  • Severely immunocompromised subjects. This exclusion category comprises: a) subjects with known infection by the human immunodeficiency virus (HIV\-1\); b) neutropenic subjects with less than 500 neutrophils/mm3; c) subjects with solid organ transplantation; d) subjects with bone marrow transplantation; e) subjects under chemotherapy; f) subjects with primary immunodeficiency; g) severe lymphopenia with less than 400 lymphocytes/mm3; h) treatment with any immunosuppressant drugs such as anti\-cytokine therapies, and treatment with oral or intravenous steroids defined as daily doses of 10mg prednisone or equivalent for longer than 3 months, or probable use of oral or intravenous steroids in the following four weeks
  • Active solid or non\-solid malignancy or lymphoma within the prior two years
  • Active participation in another research study that involves BCG administration

Outcomes

Primary Outcomes

Not specified

Similar Trials